BioVaxys reports that its MVP-S cancer vaccine combined with hormone therapy demonstrated strong immune responses and reduced tumor growth markers in a Phase 1 trial of women with HR+/HER2- breast cancer.
Sign up to receive our latest updates in your mailbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Your data is valuable and we will never sell or share it without your permission. By signing up to receive notifications from us, you agree to our Privacy policy.
